Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ponatinib Hydrochloride

FDA-approved product (tablet, oral), marketed as Iclusig, Ponatinib Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ponatinib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • Chronic myelogenous leukemia
  • Lymphoid leukemia
  • Myeloid leukemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ponatinib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ponatinib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)

    NCT04160546 · start 2020-01-17

    Registered record
    Registry ID
    NCT04160546
    Conditions
    Chronic Myeloid Leukemia, Chronic Phase
    Interventions
    Ponatinib 15 MG; Acetylsalicylic acid 100 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-01-17
    Completion
    2025-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia, Chronic Phase
    InterventionPonatinib 15 MG; Acetylsalicylic acid 100 MG
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients

    NCT03690115 · start 2019-12-02

    Registered record
    Registry ID
    NCT03690115
    Conditions
    Leukemia, Myeloid, Acute
    Interventions
    Ponatinib 30 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-12-02
    Completion
    2024-12-31
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Myeloid, Acute
    InterventionPonatinib 30 MG
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

    NCT04070443 · start 2019-11-13

    Registered record
    Registry ID
    NCT04070443
    Conditions
    Philadelphia Chromosome Positive CML; BCR-ABL Positive Chronic Myelogenous Leukemia
    Interventions
    Ponatinib; Imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2019-11-13
    Completion
    2029-06-01
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia Chromosome Positive CML; BCR-ABL Positive Chronic Myelogenous Leukemia
    InterventionPonatinib; Imatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

    NCT03838692 · start 2019-07-26

    Registered record
    Registry ID
    NCT03838692
    Conditions
    Medullary Thyroid Cancer
    Interventions
    Ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-07-26
    Completion
    2021-06-14
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedullary Thyroid Cancer
    InterventionPonatinib
    PhasePhase 2
    Registry statusWithdrawn

  • Vascular Cardiotoxicity of Ponatinib

    NCT03930394 · start 2019-05-15

    Registered record
    Registry ID
    NCT03930394
    Conditions
    Cardiotoxicity
    Interventions
    Contrast ultrasound perfusion imaging
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-05-15
    Completion
    2022-05-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiotoxicity
    InterventionContrast ultrasound perfusion imaging
    PhaseNot recorded
    Registry statusUnknown

  • Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    NCT03739814 · start 2019-05-08

    Registered record
    Registry ID
    NCT03739814
    Conditions
    B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia
    Interventions
    Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy; Inotuzumab Ozogamicin; Lumbar Puncture; Ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2019-05-08
    Completion
    2027-02-01
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia
    InterventionBiospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy +3 more
    PhasePhase 2
    Registry statusRecruiting

  • Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

    NCT04043676 · start 2019-04-30

    Registered record
    Registry ID
    NCT04043676
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Ponatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-04-30
    Completion
    2023-04-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionPonatinib
    PhasePhase 2
    Registry statusUnknown

  • A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

    NCT03515785 · start 2018-12-31

    Registered record
    Registry ID
    NCT03515785
    Conditions
    BCR-ABL Positive Acute Lymphoblastic Leukemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2018-12-31
    Completion
    2021-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBCR-ABL Positive Acute Lymphoblastic Leukemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

    NCT03704688 · start 2018-10-09

    Registered record
    Registry ID
    NCT03704688
    Conditions
    Non Small Cell Lung Cancer; KRAS Gene Mutation
    Interventions
    Trametinib 0.5 mg; Trametinib 1 MG; Trametinib 1.5 MG; Trametinib 2 mg; Ponatinib 15 MG; Ponatinib 30 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-10-09
    Completion
    2022-02-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; KRAS Gene Mutation
    InterventionTrametinib 0.5 mg; Trametinib 1 MG; Trametinib 1.5 MG; Trametinib 2 mg +2 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

    NCT03589326 · start 2018-10-04

    Registered record
    Registry ID
    NCT03589326
    Conditions
    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
    Interventions
    Ponatinib; Imatinib; Vincristine; Dexamethasone; Cytarabine; Methotrexate; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2018-10-04
    Completion
    2027-07-31
    Enrolment
    245

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
    InterventionPonatinib; Imatinib; Vincristine; Dexamethasone +3 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

    NCT03624530 · start 2018-08

    Registered record
    Registry ID
    NCT03624530
    Conditions
    Philadelphia Chromosome Positive Acute Lymphocytic Leukemia; Tyrosine Kinase Inhibitor; Minimal Residual Disease; Allogeneic Hematopoietic Stem Cell Transplantation
    Interventions
    Tyrosine kinase inhibitor (TKIs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2018-08
    Completion
    2022-07
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia; Tyrosine Kinase Inhibitor; Minimal Residual Disease; Allogeneic Hematopoietic Stem Cell Transplantation
    InterventionTyrosine kinase inhibitor (TKIs)
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

    NCT03576547 · start 2018-06-26

    Registered record
    Registry ID
    NCT03576547
    Conditions
    Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Acute Lymphoblastic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; t(9; 22)
    Interventions
    Dexamethasone; Ponatinib Hydrochloride; Rituximab; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2018-06-26
    Completion
    2024-06-19
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive; Recurrent Acute Lymphoblastic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive +4 more
    InterventionDexamethasone; Ponatinib Hydrochloride; Rituximab; Venetoclax
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®

    NCT02455024 · start 2018-03-02

    Registered record
    Registry ID
    NCT02455024
    Conditions
    Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2018-03-02
    Completion
    2019-02-19
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL
    InterventionNot recorded
    PhaseNot recorded
    Registry statusTerminated

  • Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

    NCT04048564 · start 2018-02-23

    Registered record
    Registry ID
    NCT04048564
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-02-23
    Completion
    2023-07-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

    NCT03331211 · start 2017-11-01

    Registered record
    Registry ID
    NCT03331211
    Conditions
    Leukemia, Lymphoblastic, Acute
    Interventions
    TKIs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-11-01
    Completion
    2019-09-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia, Lymphoblastic, Acute
    InterventionTKIs
    PhaseNot recorded
    Registry statusUnknown